Highlights
- Post-transplant cyclophosphamide (PTCy) is associated with a 75% reduction in the risk of Bronchiolitis Obliterans Syndrome (BOS) compared to traditional prophylaxis.
- The protective effect of PTCy against BOS is primarily mediated through its efficacy in preventing systemic chronic graft-versus-host disease (cGvHD).
- Benefits of PTCy in reducing pulmonary complications are consistent across both haploidentical and HLA-matched donor transplant settings.
- Given the poor prognosis of BOS (5-year survival <50%), PTCy represents a major therapeutic advancement in long-term transplant survivorship.
Background
Bronchiolitis obliterans syndrome (BOS) remains one of the most dreaded late complications of allogeneic hematopoietic cell transplantation (HCT). As the primary pulmonary manifestation of chronic graft-versus-host disease (cGvHD), BOS affects approximately 5% to 10% of transplant recipients. It is characterized by progressive, irreversible airflow obstruction due to the fibroproliferative occlusion of small airways. Despite advances in supportive care and immunosuppressive strategies, the prognosis for patients who develop BOS is dismal, with 5-year survival rates frequently falling below 50%.
The standard of care for GvHD prophylaxis has historically relied on the combination of calcineurin inhibitors (CNIs) and methotrexate (MTX) or mycophenolate mofetil (MMF). However, these regimens often fail to adequately prevent cGvHD, particularly in the lung. Post-transplant cyclophosphamide (PTCy) has recently emerged as a transformative alternative. Initially developed for haploidentical HCT to overcome intense T-cell-mediated alloreactivity, PTCy is now being increasingly utilized in matched sibling and unrelated donor transplants. While its ability to reduce the incidence of severe acute and chronic GvHD is well-documented, its specific impact on the development of BOS—a relatively rare but lethal organ-specific manifestation—has only recently been quantified through large-scale multicenter analyses.
Key Content
Evolution of Post-Transplant Cyclophosphamide Prophylaxis
The clinical application of PTCy is based on the selective depletion of alloreactive T-cells while sparing regulatory T-cells (Tregs) and non-alloreactive memory T-cells. This pharmacological window occurs between days +3 and +4 post-transplant. Early trials (Luznik et al., 2008) demonstrated that PTCy could safely facilitate haploidentical HCT with low rates of severe GvHD. Over the last decade, the BMT CTN 1703 trial and other phase III evidence have demonstrated the superiority of PTCy-based regimens over CNI/MTX in terms of GvHD-free, relapse-free survival (GRFS) in the matched donor setting.
The Eggleston Multicenter Cohort: Evidence for BOS Reduction
A pivotal multicenter cohort study (Eggleston et al., 2026) involving 900 patients across three major U.S. transplant centers has provided the most definitive evidence to date regarding PTCy’s impact on BOS. In this study, 276 patients received PTCy-based prophylaxis, while 624 received non-PTCy regimens. The researchers utilized strict NIH consensus criteria and clinical diagnosis to identify BOS cases, ensuring a rigorous definition of the disease.
The results revealed a profound protective effect: patients receiving PTCy had an adjusted hazard ratio (aHR) of 0.25 (95% CI: 0.09-0.74, p=0.012) for developing BOS. This translates to a 75% reduction in risk. Notably, this benefit remained statistically significant even after adjusting for potential confounders such as patient age, immunologic matching, and pre-transplant pulmonary function (FEV1).
Mediation Analysis: The Biological Link between cGvHD and BOS
To understand whether PTCy protects the lungs directly or through broader systemic immune modulation, the Eggleston study performed a mediation analysis. This statistical approach evaluated whether the reduction in BOS was independent or a result of lower overall cGvHD rates. When cGvHD was factored into the model, the hazard ratio for PTCy attenuated significantly (from 0.26 to 0.41), and the p-value lost significance (p=0.108). This indicates that the “anti-BOS” effect of PTCy is largely driven by its success in preventing cGvHD. Biologically, this suggests that the high-dose cyclophosphamide effectively eliminates the donor T-cell clones responsible for the inflammatory and subsequent fibrotic cascades that lead to bronchiolar destruction.
Evidence Across Donor Types
A common concern in earlier studies was that the benefits of PTCy might be limited to haploidentical (HID) transplants, where it is most frequently used. However, the Eggleston analysis performed a sensitivity analysis excluding HID transplants and found that the protective effect was maintained (HR: 0.24, 95% CI: 0.07-0.77, p=0.016). This reinforces the growing consensus that PTCy-based prophylaxis should be considered a preferred strategy for a wider range of HCT recipients, including those with matched donors, to mitigate the risk of pulmonary GvHD.
Expert Commentary
The findings from the Eggleston et al. study represent a significant milestone in pulmonary transplant medicine. For years, clinicians have struggled to find effective ways to prevent BOS, often relying on intensive post-transplant monitoring and early intervention with FAM (fluticasone, azithromycin, and montelukast) or extracorporeal photopheresis. These interventions, however, are largely reactive.
The proactive use of PTCy shifts the focus from treatment to prevention. From a mechanistic standpoint, the sparing of regulatory T-cells by PTCy is particularly relevant for the lung, as Tregs are known to play a critical role in maintaining mucosal tolerance and preventing the aberrant fibrotic responses characteristic of BOS. However, it is important to note that while PTCy reduces the risk, it does not eliminate it. Approximately 10% of patients in traditional cohorts develop BOS, and even with PTCy, a residual risk remains. Furthermore, this study was retrospective; while the sample size is robust and the multicenter design adds weight, prospective randomized trials specifically powered for pulmonary endpoints would provide the highest level of evidence.
One controversy remains regarding the optimal dose and combination of PTCy. In the BMT CTN 1703 trial, PTCy was combined with Tacrolimus and MMF. Clinicians must balance the reduction in cGvHD/BOS against the potential risks of delayed engraftment or infectious complications associated with more intensive T-cell depletion. Nevertheless, for patients with pre-existing risk factors for pulmonary complications or those receiving grafts from donors with higher GvHD potential (e.g., peripheral blood grafts from unrelated donors), the evidence strongly favors a PTCy-based approach.
Conclusion
The integration of post-transplant cyclophosphamide into the standard GvHD prophylaxis armamentarium marks a new era in HCT. The Eggleston multicenter study provides compelling evidence that PTCy significantly reduces the incidence of BOS, a primary driver of post-transplant mortality. By effectively mediating the prevention of cGvHD, PTCy offers a viable pathway to improving long-term respiratory health and overall survival in transplant recipients. Future research should focus on identifying biomarkers that can predict which patients remain at risk despite PTCy and exploring whether combining PTCy with other novel agents can further eradicate this devastating complication.
References
- Eggleston RH, Alkhateeb H, Pennington KM, et al. Post-transplant Cyclophosphamide Reduces Bronchiolitis Obliterans Syndrome Risk Through Chronic Graft-versus-Host Disease Prevention: A Multicenter Cohort Study. Chest. 2026; PMID: 41850483.
- Holtan SG, Hamadani M, Wu J, et al. Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388(25):2338-2348. PMID: 37342957.
- Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650. PMID: 18511636.
- Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. PMID: 25545689.
